Stereotactic radiotherapy (SRS/SRT/SBRT) for metastatic breast cancer


Study PI:

Dr. med. David Krug
University Hospital Kiel
david.krug@uksh.de

PD Dr. Maciana Nona Duma
University Hospital Jena
marciana-nona.duma@med.uni-jena.de

Study design:

● Multicenter, international retrospective study

Study objective:

● To analyse the efficacy of SRS/SRT and SBRT for metastases from breast cancer

Patient population to be included:

● Women with metastatic breast cancer and one or more metastases treated with SRS/SRT/SBRT; including oligometastatic and polymetastatic disease

Project plan:

● Establishment of a retrospective database of patients with breast cancer who received SRS/SRT/SBRT to one or more metastatic sites.
● Collection of data regarding disease status (synchronous vs. metachronous metastatic disease, oligometastatic vs. polymetastatic oligoprogressive disease)
● Collection of data regarding radiotherapy according to ICRU 91 and standard practice for the working group
● Collection of data regarding biological subtype (ER/PR/HER2-status, grading)
● Collection of data regarding systemic therapy (before, during and after stereotactic radiotherapy)
● Endpoints: local control, progression-free survival, overall survival, acute (≤ 90 days from radiotherapy) and chronic (> 90 days from radiotherapy) toxicity

Project status:

● Ethic approval obtained for Kiel
● Data collection started in November 2020
● Data collection to be finalized until mid 2021

Interested collaborators are welcome to join the study.